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Abstract
Outcome of systemic peripheral T-cell lymphomas (PTCL) is unsatisfactory and no con-
trolled clinical study guides the therapy. Phase II studies suggest to consolidate response
achieved after front-line treatment with stem cell transplant (SCT). We retrospectively evalu-
ate the impact of front-line SCT consolidation in a single Center cohort of 209 patients treat-
ed during the last two decades. Median age was 49 years (range 15-85) with a prevalence
of male sex (61%), advanced stage (68%) while IPI was>2 in 44%. Primary treatment was
MACOP-B (39%) CHO(E)P (39%), intensive regimens (18%) or others (4%). Complete re-
sponse to primary treatment (i.e. before SCT) was 60% (5% partial remission). Forty-four
patients further proceeded to SCT while 92 did not receive consolidation. Outcome of prima-
ry responders was good, with a 3-year overall survival of 74% (82% in ALCL ALK+ and 69%
for the other histologies). By multivariate analysis a better overall survival was significantly
associated with IPI<2 (P=0.001), primary response (P=0.000), and ALCL ALK+ (P=0.012).
The multivariate analysis performed on responders, showed that only IPI was predictive of
a better survival while ALCL ALK+ and undergoing SCT were not. Response to primary
treatment rather than post-remission programs is the crucial determinant of PTCL outcome.
Introduction
Systemic peripheral T-cell lymphomas (PTCL) are a rare and heterogeneous group of non-
Hodgkin lymphomas characterized by an aggressive clinical course and poor
treatment response.
Several retrospective studies have shown that long-term survival of most PTCL do not ex-
ceed 30–40%, with systemic anaplastic large cell lymphoma (ALCL) expressing the anaplastic
large cell lymphoma kinase (ALK) protein being the exception[1–4]. The optimal treatment of
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these lymphomas is still a matter of debate as conventional therapy based on CHOP/CHOP-
like regimens provided unsatisfactory outcome[5, 6]. Attempts to improve response and sur-
vival with early treatment intensification led to similarly disappointing results[7–11]. Several
retrospective studies [12–15] and few small-sized phase II trials[16–20] suggested that consoli-
dation of the first response with high dose therapy (HDT) followed by autologous stem cell
transplant (SCT) is a feasible option and may guarantee better disease control, with long-term
overall survival (OS) up to 60–70%. This concept has been tested in a large phase II trial enroll-
ing 160 histologically proved patients that reported an encouraging 5-year OS and progression
free survival (PFS) as good as 51% and 44%, respectively[21]. Despite these interesting results,
no comparative trial is available and it is not clear whether HDT plus autologous SCT should
be considered a standard treatment in all PTCL subgroups. In addition, the role of allogeneic
SCT as front-line treatment for these patients have been recently reported in a phase II clinical
study[22].
In this study, we retrospectively evaluated the outcome of PTCL patients treated in the last




Eligible for this retrospective analysis were untreated patients with systemic PTCL diagnosed
between January 1990 and December 2012 at “Papa Giovanni XXIII”Hospital (formerly “Ospe-
dali Riuniti”) of Bergamo. Patients treated with a palliative intent, those without pathological
material suitable for revision and primary cutaneous T-cell lymphomas were excluded from
the study. The diagnostic slides were independently reviewed by two hematopathologists and
classified according to the 2008 WHO classification[23]. When necessary, immunostains were
performed i.e. ALK in ALCL. Clinical information was gathered from the electronic charts.
When necessary, the paper charts were reviewed. Patient’s written informed consent for the
retrospective use of clinical data gathered from the electronic charts was obtained in all cases
and this procedure was approved from Hospital’s Ethic Committee (“Comitato Etico della Pro-
vincia di Bergamo”). The study was approved and conducted in accordance with the Italian
laws and the Declaration of Helsinki.
Treatments and outcome evaluation
Treatments included standard CHOP (cyclophosphamide, doxorubicin, vincristine, and pred-
nisone), CHOP with etoposide (CHOEP), MACOP-B[24] or intensive therapy including both
clinical trials[16, 22] and intensive acute lymphoblastic leukemia-like schemes[25]. Patients
with stage II–IV PTCL (excluding ALCL ALK positive after 2003), age<60 years with no med-
ical contraindications were considered eligible to first-line SCT consolidation if a clinical re-
sponse is achieved after a full course of treatment. Patients proceeding to autologous SCT
received an additional stem cell mobilizing cycle (MAD or high-dose cyclophosphamide) fol-
lowed by HDT according to BEAM (BCNU, etoposide, cytosine arabinoside, and melphalan)
plus autologous SCT. Front-line allogeneic SCT was performed within a clinical trial[22].
Treatment response was defined according to the 1999 International Working Group criteria
[26] and was recorded after the primary treatment (i.e. CHOP, CHOEP, MACOP-B or inten-
sive therapy) and after SCT consolidation when applicable.
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Statistical analysis
The long-term outcome was assessed in terms of overall survival (OS), progression-free surviv-
al (PFS) and disease-free survival (DFS) defined according to Cheson criteria[26]. The OS was
defined as the time from the start of treatment to death for any cause. The PFS was defined as
the time from the start of treatment to disease progression or death for any cause. The DFS was
defined as the time from documentation of complete response to relapse or death for any
cause. All the variables were analyzed by the Kaplan-Meier method. Patients were censored at
the date of last contact, follow-up was updated in September 2013 and all living patients had
been observed at least once in the previous 3 months. Differences in survival between groups
were identified by generalized log-rank analysis. Multivariate analysis for survival was per-
formed by Cox regression model; proportional hazards assumption was tested. A chi-squared




Two-hundred and nine patients were included in the retrospective analysis. The baseline clini-
cal characteristics are summarized in Table 1. Median age at diagnosis was 49 years with a
male predominance (61%). In the majority of the cases (68%), patients had an advanced stage
disease with an intermediate-high or high International Prognostic Index (IPI)[27] in 44%.
There was a prevalence of ALCL (51%), particularly ALK positive (34%). These latter patients
were characterized by lower median age than other histologies (42.6 vs 57.1 years, P =
<0.0001) and showed lower IPI and PIT scores (P = 0.0017 and 0.0392, respectively). Primary
treatment was MACOP-B in most of the cases until 2003 and CHOP or CHOEP later on while
18% of the patients received intensive treatments (Table 2).
Response and survival in the whole cohort
Overall response rate to primary treatment (i.e. before SCT consolidation) was 65% with a
complete response (CR) achieved in 60% of patients (Table 2). Of note, 13% of the patients
died early during treatment (<6 months), with a similar incidence among the three treatment
categories. Treatment response was slightly better in ALCL ALK positive patients than the oth-
ers, however the result was not statistically significant (P = 0.130). Consolidation of first re-
sponse with SCT was performed in 44 patients (21%). In most of these cases (N = 41/44, 93%)
the stem cell source was autologous while an allogeneic SCT was performed only in 3 cases. Six
of the seven patients undergoing autologous SCT in partial remission (PR) achieved the CR. Of
the three patients undergoing allogeneic SCT, one deceased by pulmonary aspergillosis shortly
after engraftment, one deceased by grade IV cutaneous and intestinal acute graft versus host
disease (GVHD) at day 64 and the last patient is alive and well after nearly 5 years.
Overall survival, PFS and DFS of patients with ALCL ALK positive versus other histologies
are presented in Fig. 1, while the impact of the different histology on clinical outcome is shown
in S1 Fig.
It was not possible to evaluate the impact of specific histology on outcome due to the rela-
tively small sample size. Interestingly, the 5 patients with Enteropathy-Associated T-cell Lym-
phoma (EATL) who performed autologous SCT remained all disease free after a median
follow-up of 5.61 (0.63–7.93) years.
By univariate analysis, an inferior clinical outcome was related to IPI>2 [Hazard Ratio
(HR) 2.90, P<0.001], Prognostic Index for PTCL-unspecified (PIT)[28]>2 (HR 3.29,
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P<0.001), the male sex (HR 1.60, P = 0.016), the lack of a clinical response to primary treat-
ment (HR 6.61, P<0.001), PTCL not otherwise specified (NOS) histology compared with
ALCL ALK positive (HR 2.54, P<0.001) and MACOP-B treatment (HR 0.59, P = 0.040) while
year of treatment>2003 (HR 1.32, P = 0.153) did not show any impact. By multivariate analy-
sis IPI, ALCL ALK positive histology and primary treatment response were independent pre-
dictors of outcome (Table 3).
Response and survival according to primary treatment response
Overall survival according to primary treatment response shows that patients responding (CR/
PR) to primary treatment fares well, with a global 3-year OS of 74% that was 82% in ALCL
ALK positive patients and 69% for the other histologies (Fig. 1D). We next analyzed the effect
Table 1. Patients Characteristics.
All N (%) Non-ALCL ALK+ N (%) ALCL ALK+ N (%) P
All patients 209 (100) 139 (66) 70 (34)
Age
Median (range) 49.3 (15–85) 57.1 (19–85) 42.6 (15–82) <0.0001
60 69 (33) 60 (43) 9 (13) <0.0001
Gender
Male 128 (61) 80 (58) 48 (69) 0.1228
Histology
PTCL-NOS 67 (32) 67 (48)
ALCL ALK positive 70 (34) - 70 (100)
ALCL ALK negative 36 (17) 36 (26) -
AITL 21 (10) 21 (15) -
EATL 10 (5) 10 (7) -
Others 5 (2) 5 (4) -
Ann Arbor Stage
III–IV 143 (68) 102 (73) 41 (59) 0.0297
ECOG PS
2 87 (42) 54 (39) 33 (47) 0.2464
Serum LDH Level
> ULN 92 (44) 64 (46) 28 (40) 0.3585
Extranodal Sites
>1 68 (33) 54 (39) 14 (20) 0.0057
Bone marrow involvement
Yes 22 (12)* 18 (15)** 4 (7)*** 0.1153
IPI
>2 91 (44) 71 (51) 20 (29) 0.0017
PIT
>2 26 (15)* 22 (18)** 4 (7)*** 0.0392
Legend:
* N = 179;
** N = 120;
*** N = 59;
PTCL-NOS: Peripheral T-Cell Lymphoma Not Otherwise Speciﬁed; ALCL: Anaplastic Large-Cell Lymphoma; ALK: Anaplastic Large Cell Lymphoma
Kinase; EATL: Enteropathy-Associated T-cell Lymphoma; AITL: Angioimmunoblastic T-cell Lymphoma; Others: includes hepatosplenic T-cell lymphoma
(N = 3) and extranodal T/NK-cell lymphoma nasal type (N = 2);IPI: International Prognostic Index; PIT: Prognostic Index for PTCL-NOS
doi:10.1371/journal.pone.0121822.t001
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Table 2. Treatments and Outcome.
All N (%) Non-ALCL ALK+ N (%) ALCL ALK+ N (%) P
All patients 209 (100) 139 (67) 70 (33)
Primary treatment
CHO(E)P 82 (39) 65 (47) 17 (24) 0.0001
MACOP-B 81 (39) 39 (28) 42 (60)
Intensive regimens 37 (18) 29 (21) 8 (12)
Others 9 (4) 6 (4) 3 (4)
Response to primary treatment
CR 126 (60) 79 (57) 47 (67) 0.1300
PR 10 (5) 6 (4) 4 (6)
SD/PD 45 (22) 30 (22) 15 (21)
Early death 28 (13) 24 (17) 4 (6)
Legend: Others: includes MetAspDex regimen, ACVBP or ACOD; CR: Complete Remission; PR: Partial
Remission; SD: Stable Disease; PD: Progressive Disease; SCT: Stem Cell Transplant. Early death indicates
patients deceasing <6 months from diagnosis.
doi:10.1371/journal.pone.0121822.t002
Fig 1. Overall survival (A), progression-free survival (B) and disease free survival (C) in the whole cohort according to histologic subgroup.Overall
survival according to primary treatment response (E). ALCL: anaplastic large cell lymphoma; ALK: anaplastic large cell lymphoma kinase; CR: complete
remission; PR: partial remission; NR: no response, including stable and progressive disease.
doi:10.1371/journal.pone.0121822.g001
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of consolidation with autologous SCT in our cohort of responsive patients. For this purpose,
we excluded the three patients receiving allogeneic SCT, and analyzed our patient population
in two different cohort according to histology i.e. ALCL ALK positive and others. With the ex-
ception of age, the presenting clinical characteristic of non-ALCL ALK positive patient who re-
ceived or not an autologous SCT after achieving a clinical response did not significantly differ
(Table 4).
Conversely, transplanted patients with ALCL ALK positive were at higher risk according to
stage, PIT, and probably IPI. Of note, autologous SCT converted a PR in CR in 6 out of 7 cases.
By multivariate analysis, only IPI>2 was associated with an inferior survival (HR 2.37,
P = 0.018), while the clinical benefit related to SCT consolidation and ALCL ALK positive his-
tology was not confirmed (Table 5). When excluding ALCL ALK positive patients from the
analysis, the results did not change and receiving SCT was not associated to better prognosis
(Table 6).
The clinical outcome of the 45 patients not responding to primary treatment was remark-
ably poor, with a 1-year OS of 19% (Fig. 1D) that was as low as 4% when excluding ALCL ALK
positive patients. For these patients a salvage autologous SCT was performed in 7 cases (16%)
and an allogeneic SCT in 6 (13%). Long-term survivors were only 6 patients (all with a diagno-
sis of ALCL ALK positive) who received either an allogeneic (N = 3) or autologous (N = 3)
SCT. On the contrary, outcome of patients treated with chemotherapy only was very poor,
with only one long-term survivor that, however, experienced multiple chemosensitive relapse.
Twenty-eight patients (13%) died early during treatment. The median age of this latter co-
hort of patients was 62.0 years (range 35–84), 21 patients (75%) showed an IPI>2 and the dis-
ease was symptomatic in 20 cases (71%). In most of the cases (89%) cause of death was
infection, in large part associated to evidence of insufficient disease control.
Table 3. Multivariate analysis for overall survival of the whole cohort.
Hazard Ratio CI 95% P 3-year OS 10-year OS
Age
< 60 1.00 59% 47%
60 1.20 0.77–1.88 0.4251 38% 26%
IPI
 2 1.00 68% 56%
> 2 1.82 1.21–2.74 0.0041 32% 21%
Primary treatment response
NR/EXITUS 1.00 12% 11%
CR/PR 0.14 0.09–0.22 <0.0001 74% 57%
Histology
ALCL ALK positive 1.00 70% 56%
Others 2.78 1.68–4.59 <0.0001 43% 33%
Chemotherapy scheme
CHO(E)P 1.00 42% 28%
MACOP-B 1.00 0.57–1.76 0.9998 62% 50%
Intensiﬁed 0.78 0.46–1.34 0.3760 51% 45%
Year of treatment
 2003 1.00 57% 44%
> 2003 0.77 0.48–1.25 0.2906 44% -
doi:10.1371/journal.pone.0121822.t003
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Discussion
Over the last two decades, consolidation of first-response with HDT and autologous SCT has
been explored in systemic PTCL with the intent to reduce the unacceptable high relapse rate of
this group of lymphomas. The heterogeneity and relative rarity of these diseases was a great
limit to perform informative trials and only few, small sized non-comparative prospective stud-
ies have been available until recently. Several studies have shown a long-term (3 years) OS
ranging from 48 to 73% after HDT and autologous SCT[15–18, 20]. Recently, a large phase II
trial including 160 histologically proven PTCL, with the exclusion of ALCL ALK positive, re-
ported encouraging survival data, with a 5-year OS and PFS of 51% and 44%, using a dose
dense CHOEP-14 induction therapy (CHOP-14 if age>60 years) and autologous SCT in re-
sponders[21]. More recently, allogeneic SCT has been as well explored in first-line setting[22].
Table 4. Clinical Characteristics of Patients Responsive to Primary Treatment.
Non-ALCL ALK+ ALCL ALK+
With SCT N (%) Without SCT N (%) P With SCT N (%) Without SCT N (%) P
All patients 26 (32) 56 (68) 15 (29) 36 (71)
Age
Median (range) 45.3 (19–62) 63.9 (22–85) 0.0002 31.4 (20–59) 44.1 (17–79) 0.0265
60 2 (8) 32 (57) <0.0001 0 (0) 5 (14) 0.1286
Sex
Male 16 (62) 29 (52) 0.4089 9 (60) 24 (67) 0.6499
Histology
PTCL-NOS 7 (27) 28 (50) 0.0209 0 0 -
ALCL ALK positive 0 0 15 (100) 36 (100)
ALCL ALK negative 8 (31) 15 (27) 0 0
AITL 4 (15) 11 (20) 0 0
EATL 5 (19) 1 (1.5) 0 0
Others 2 (8) 1 (1.5) 0 0
Ann Arbor Stage
III–IV 14 (54) 39 (70) 0.1638 12 (80) 16 (44) 0.0201
IPI
>2 6 (23) 23 (41) 0.1127 6 (40) 6 (17) 0.0735
PIT
>2 2 (9) 3 (6) 0.6185 2 (13) 0 (0) 0.0519
Relapse/progression
Yes 9 (35) 22 (39) 0.6849 2 (13) 13 (36) 0.1038
Primary treatment response
CR 21 (81) 55 (98) 0.0048 13 (87) 34 (94) 0.3465
PR 5 (19) 1 (2) 2 (13) 2 (6)
Final response (after autologous SCT)
CR 25 (96) - - 15 (100) - -
PR 1 (4) - - 0 - -
Legend: PTCL-NOS: Peripheral T-Cell Lymphoma Not Otherwise Speciﬁed; ALCL: Anaplastic Large-Cell Lymphoma; ALK: Anaplastic Large Cell
Lymphoma Kinase; EATL: Enteropathy-Associated T-cell Lymphoma; AITL: Angioimmunoblastic T-cell Lymphoma; Others: includes hepatosplenic T-cell
lymphoma (N = 3) and extranodal T/NK-cell lymphoma nasal type (N = 2); SCT: Stem Cell Transplant
doi:10.1371/journal.pone.0121822.t004
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In this study, we present the outcome of a large cohort of histologically confirmed PTCL pa-
tients derived from a single Institution and followed up for a prolonged period of time. To our
knowledge, this is the first report that, though retrospectively, describes the outcome of re-
sponding patients according to subsequent consolidation strategy. Our results indicate that re-
sponse to primary treatment is the key variable for the long term prognosis and consolidation
with HDT and SCT may not be crucially important for most of the complete responders. How-
ever, in some patients such as those with EATL, first-line SCT looked particularly beneficial
when performed in CR. Although not statistically significant due to the limited sample size,
Table 5. Multivariate analysis for overall survival of the responders*.
Variables Hazard Ratio CI 95% P 3-year OS 10-year OS
Age
< 60 1.00 79% 61%
60 1.22 0.58–2.58 0.6013 63% 47%
IPI
 2 1.00 80% 64%
> 2 2.14 1.14–4.02 0.0174 64% 41%
1st line autologous SCT consolidation
Performed 0.66 0.33–1.33 0.2443 82% 65%
Histology
ALCL ALK positive 1.00 82% 64%
Others 1.65 0.88–3.10 0.1208 70% 41%
Chemotherapy scheme
CHO(E)P 1.00 69% 46%
MACOP-B 1.18 0.60–2.31 0.6300 74% 58%
Intensiﬁed 0.69 0.25–1.93 0.4819 88% 82%
Legend:
* excluding 3 patients treated with allogeneic SCT
doi:10.1371/journal.pone.0121822.t005
Table 6. Multivariate analysis for overall survival of the responders* (excluding ALCL ALK+).
Variables Hazard Ratio CI 95% P 3-year OS 10-year OS
Age
< 60 1.00 79% 61%
60 1.59 0.70–3.61 0.2685 57% 37%
IPI
 2 1.00 78% 66%
> 2 2.65 1.29–5.43 0.0077 55% 25%
1st line autologous SCT consolidation
Performed 0.97 0.41–2.27 0.9436 80% 53%
Chemotherapy scheme
CHO(E)P 1.00 62% 38%
MACOP-B 0.77 0.35–1.72 0.5311 73% 56%
Intensiﬁed 0.68 0.24–1.93 0.4702 85% 76%
Legend:
* excluding 3 patients treated with allogeneic SCT
doi:10.1371/journal.pone.0121822.t006
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these data are in line with other recently published.[29] In addition, in some patients we could
observe the ability of SCT consolidation in converting a partial response into a complete one.
Median age of our cohort was lower and the proportion of ALCL ALK positive patients was
higher compared to other series.[4] This finding may reflect the pattern of referral as our Cen-
ter is the tertiary care referral center, and is accordingly similar to those reported in other re-
port, for example in a German series of 320 patients enrolled in clinical trials median age was
50 years and 60% of the patients had a diagnosis of ALCL (41% ALK positive)[9]. We included
in the current analysis patients with ALK positive ALCL, that are not usually considered eligi-
ble for consolidation therapy, despite the severe prognosis of high risk disease[3]. Reason for
this choice were the homogeneous good prognosis across histologies in responding patients,
confirmed by multivariate analysis. Additionally, we could confirm that the results of the study
did not change excluding ALCL ALK positive patients.
The role of allogeneic transplantation as a front line consolidation treatment option could
not be addressed by this study and is the matter of investigation of a different ad hoc designed
clinical trial. Therefore, while waiting for additional data, allogeneic SCT consolidation should
be used with caution in patients responding to a first line treatment.
The primary determinant of outcome resulted to be treatment response, and despite several
clinical trials have been addressing the unsatisfactory outcome of PTCL in the last two decades,
6 to 8 cycles of chemotherapy with CHOP with or without etoposide (CHOEP) still remains
the standard[30, 31]. Several novel molecules are currently facing the clinical ground and there
is high expectation from the combination of standard chemotherapy with newer biological
agents[32]. Despite the rapid growth of clinical trials in PTCL driven by new drugs, the role of
consolidation with HDT and autologous SCT remains not addressed, yet.
Conversely, since primary response is such a key factor for outcome, there is an urgent need
to develop strategies aimed at the early identification of poor responders. In this respect, the
role of interim 18F-fluorodeoxyglucose—positron emission tomography (FDG—PET) remains
controversial but in general, differently from Hodgkin disease[33], it does not provide informa-
tive data as to chemosensitivity of this group of patients[34–36].
In conclusion, our study underlines the crucial importance of increasing the quality of re-
sponse to primary treatment and the need of new drugs or innovative treatment strategies to
achieve such a goal. Among these latter treatment strategies, the role of a consolidation of first
remissions with autologous stem cell transplantation should always be considered[37] but its
benefit remains to be proven by well conducted comparative, prospective, clinical trials.
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